questionsmedicales.fr
Virus
Virus à ARN
Retroviridae
Lentivirus
Lentivirus ovins-caprins
Virus maedi-visna
Virus maedi-visna : Questions médicales fréquentes
Termes MeSH sélectionnés :
Angiotensin Receptor Antagonists
Diagnostic
5
Virus maedi-visna
Diagnostic médical
Tests de diagnostic
Virus maedi-visna
Symptômes
Virus maedi-visna
Virus maedi-visna
Infection virale
Diagnostic précoce
Virus maedi-visna
Symptômes
5
Symptômes
Virus maedi-visna
Symptômes neurologiques
Virus maedi-visna
Portage asymptomatique
Virus maedi-visna
Évolution des symptômes
Virus maedi-visna
Prévention
5
Prévention
Virus maedi-visna
Dépistage
Virus maedi-visna
Hygiène
Virus maedi-visna
Vaccination
Virus maedi-visna
Quarantaine
Virus maedi-visna
Traitements
5
Traitement
Virus maedi-visna
Antiviraux
Virus maedi-visna
Gestion des animaux
Virus maedi-visna
Vaccins
Virus maedi-visna
Nutrition
Virus maedi-visna
Complications
5
Complications
Virus maedi-visna
Fréquence des complications
Virus maedi-visna
Production animale
Virus maedi-visna
Complications irréversibles
Virus maedi-visna
Pronostic
Virus maedi-visna
Facteurs de risque
5
Facteurs de risque
Virus maedi-visna
Races animales
Virus maedi-visna
Environnement
Virus maedi-visna
Pratiques d'élevage
Virus maedi-visna
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Virus maedi-visna : Questions médicales les plus fréquentes",
"headline": "Virus maedi-visna : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Virus maedi-visna : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-20",
"dateModified": "2025-04-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Virus maedi-visna"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lentivirus ovins-caprins",
"url": "https://questionsmedicales.fr/mesh/D017972",
"about": {
"@type": "MedicalCondition",
"name": "Lentivirus ovins-caprins",
"code": {
"@type": "MedicalCode",
"code": "D017972",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.820.650.589.600"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Virus maedi-visna",
"alternateName": "Visna-maedi virus",
"code": {
"@type": "MedicalCode",
"code": "D014790",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xujie Duan",
"url": "https://questionsmedicales.fr/author/Xujie%20Duan",
"affiliation": {
"@type": "Organization",
"name": "College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China."
}
},
{
"@type": "Person",
"name": "Xiaona Shi",
"url": "https://questionsmedicales.fr/author/Xiaona%20Shi",
"affiliation": {
"@type": "Organization",
"name": "College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China."
}
},
{
"@type": "Person",
"name": "Shuying Liu",
"url": "https://questionsmedicales.fr/author/Shuying%20Liu",
"affiliation": {
"@type": "Organization",
"name": "College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China."
}
},
{
"@type": "Person",
"name": "Stefán R Jónsson",
"url": "https://questionsmedicales.fr/author/Stef%C3%A1n%20R%20J%C3%B3nsson",
"affiliation": {
"@type": "Organization",
"name": "Institute for Experimental Pathology, University of Iceland, Keldur, Reykjavik 112, Iceland."
}
},
{
"@type": "Person",
"name": "Yalçın Yaman",
"url": "https://questionsmedicales.fr/author/Yal%C3%A7%C4%B1n%20Yaman",
"affiliation": {
"@type": "Organization",
"name": "Siirt University Faculty of Veterinary Medicine, Department of Genetics, Siirt, Türkiye."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Synthesis, Characterization and Application of a MIP-polyHIPE for Selective Extraction of Angiotensin II Receptor Antagonists Residues in Natural Waters.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36981793",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20064878"
}
},
{
"@type": "ScholarlyArticle",
"name": "Angiotensin receptor blocker use is associated with upregulation of the memory-protective angiotensin type 4 receptor (AT",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/35969296",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11357-022-00639-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Decoding Angiotensin Receptors: TOMAHAQ-Based Detection and Quantification of Angiotensin Type-1 and Type-2 Receptors.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37681524",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.123.030791"
}
},
{
"@type": "ScholarlyArticle",
"name": "Kidney Outcomes Following Angiotensin Receptor-Neprilysin Inhibitor vs Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy for Thrombotic Microangiopathy.",
"datePublished": "2024-09-03",
"url": "https://questionsmedicales.fr/article/39264627",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.32862"
}
},
{
"@type": "ScholarlyArticle",
"name": "Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction.",
"datePublished": "2022-11-29",
"url": "https://questionsmedicales.fr/article/36459752",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.amjcard.2022.10.026"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Virus",
"item": "https://questionsmedicales.fr/mesh/D014780"
},
{
"@type": "ListItem",
"position": 3,
"name": "Virus à ARN",
"item": "https://questionsmedicales.fr/mesh/D012328"
},
{
"@type": "ListItem",
"position": 4,
"name": "Retroviridae",
"item": "https://questionsmedicales.fr/mesh/D012190"
},
{
"@type": "ListItem",
"position": 5,
"name": "Lentivirus",
"item": "https://questionsmedicales.fr/mesh/D016086"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lentivirus ovins-caprins",
"item": "https://questionsmedicales.fr/mesh/D017972"
},
{
"@type": "ListItem",
"position": 7,
"name": "Virus maedi-visna",
"item": "https://questionsmedicales.fr/mesh/D014790"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Virus maedi-visna - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Virus maedi-visna",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Virus maedi-visna",
"description": "Comment diagnostiquer une infection par le virus maedi-visna ?\nQuels tests sont utilisés pour le virus maedi-visna ?\nLes symptômes aident-ils au diagnostic ?\nPeut-on diagnostiquer le virus chez les animaux asymptomatiques ?\nQuelle est l'importance du diagnostic précoce ?",
"url": "https://questionsmedicales.fr/mesh/D014790?mesh_terms=Angiotensin+Receptor+Antagonists#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Virus maedi-visna",
"description": "Quels sont les symptômes principaux du virus maedi-visna ?\nLes symptômes varient-ils selon l'âge des moutons ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes sont-ils toujours présents ?\nComment évoluent les symptômes au fil du temps ?",
"url": "https://questionsmedicales.fr/mesh/D014790?mesh_terms=Angiotensin+Receptor+Antagonists#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Virus maedi-visna",
"description": "Comment prévenir l'infection par le virus maedi-visna ?\nLes tests de dépistage sont-ils efficaces ?\nQuelles mesures d'hygiène sont recommandées ?\nLes animaux doivent-ils être vaccinés ?\nComment gérer les nouveaux animaux dans un troupeau ?",
"url": "https://questionsmedicales.fr/mesh/D014790?mesh_terms=Angiotensin+Receptor+Antagonists#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Virus maedi-visna",
"description": "Quel est le traitement principal pour le virus maedi-visna ?\nPeut-on utiliser des antiviraux contre ce virus ?\nComment gérer les animaux infectés ?\nY a-t-il des vaccins disponibles ?\nQuel rôle joue la nutrition dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014790?mesh_terms=Angiotensin+Receptor+Antagonists#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Virus maedi-visna",
"description": "Quelles complications peuvent survenir avec le virus maedi-visna ?\nLes complications sont-elles fréquentes ?\nComment les complications affectent-elles la production ?\nLes complications sont-elles réversibles ?\nQuel est le pronostic pour les animaux infectés ?",
"url": "https://questionsmedicales.fr/mesh/D014790?mesh_terms=Angiotensin+Receptor+Antagonists#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Virus maedi-visna",
"description": "Quels sont les facteurs de risque d'infection ?\nLe stress augmente-t-il le risque d'infection ?\nLes races de moutons sont-elles affectées différemment ?\nL'environnement joue-t-il un rôle dans l'infection ?\nLes pratiques d'élevage influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D014790?mesh_terms=Angiotensin+Receptor+Antagonists#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection par le virus maedi-visna ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sérologiques et des analyses PCR pour détecter le virus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le virus maedi-visna ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et PCR sont couramment utilisés pour identifier le virus dans le sang."
}
},
{
"@type": "Question",
"name": "Les symptômes aident-ils au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes cliniques comme la pneumonie et l'encéphalite orientent le diagnostic."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer le virus chez les animaux asymptomatiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests sérologiques peuvent détecter le virus même sans symptômes visibles."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du diagnostic précoce ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic précoce permet de mieux gérer la maladie et de limiter sa propagation."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux du virus maedi-visna ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent toux, difficultés respiratoires et troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge des moutons ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes animaux peuvent présenter des symptômes plus graves que les adultes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des signes neurologiques comme des tremblements et des troubles de la coordination peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains animaux peuvent être porteurs sans montrer de symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Comment évoluent les symptômes au fil du temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver progressivement, menant à des complications graves."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'infection par le virus maedi-visna ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par l'isolement des animaux infectés et des pratiques d'élevage saines."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage régulier des troupeaux permet de détecter et d'éliminer les animaux infectés."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures d'hygiène strictes, comme le nettoyage des équipements, sont essentielles."
}
},
{
"@type": "Question",
"name": "Les animaux doivent-ils être vaccinés ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien qu'il n'y ait pas de vaccin, la vaccination contre d'autres maladies est recommandée."
}
},
{
"@type": "Question",
"name": "Comment gérer les nouveaux animaux dans un troupeau ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les nouveaux animaux doivent être testés et mis en quarantaine avant d'intégrer le troupeau."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour le virus maedi-visna ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique; la gestion des symptômes est essentielle."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des antiviraux contre ce virus ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'y a pas d'antiviraux efficaces spécifiquement pour le virus maedi-visna."
}
},
{
"@type": "Question",
"name": "Comment gérer les animaux infectés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les animaux infectés doivent être isolés et traités symptomatiquement pour améliorer leur confort."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins disponibles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de vaccin commercialement disponible contre le virus maedi-visna."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la nutrition dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne nutrition peut aider à renforcer le système immunitaire des animaux infectés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le virus maedi-visna ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent pneumonie chronique et encéphalite, pouvant être mortelles."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications sont courantes chez les animaux infectés, surtout sans traitement."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la production ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la productivité des animaux, affectant la rentabilité de l'élevage."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais beaucoup sont irréversibles et graves."
}
},
{
"@type": "Question",
"name": "Quel est le pronostic pour les animaux infectés ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le pronostic dépend de la gravité des symptômes; beaucoup développent des complications graves."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'infection ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le stress, et la densité de population dans le troupeau."
}
},
{
"@type": "Question",
"name": "Le stress augmente-t-il le risque d'infection ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affaiblir le système immunitaire, augmentant le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les races de moutons sont-elles affectées différemment ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines races peuvent être plus susceptibles à l'infection en raison de leur génétique."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans l'infection ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement surpeuplé et insalubre favorise la propagation du virus."
}
},
{
"@type": "Question",
"name": "Les pratiques d'élevage influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des pratiques d'élevage inadéquates augmentent le risque de transmission du virus."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 15/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China.
Publications dans "Virus maedi-visna" :
3 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China.
Publications dans "Virus maedi-visna" :
3 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China. liushuying1968@imau.edu.cn.
Publications dans "Virus maedi-visna" :
3 publications dans cette catégorie
Affiliations :
Institute for Experimental Pathology, University of Iceland, Keldur, Reykjavik 112, Iceland.
Publications dans "Virus maedi-visna" :
3 publications dans cette catégorie
Affiliations :
Siirt University Faculty of Veterinary Medicine, Department of Genetics, Siirt, Türkiye.
Publications dans "Virus maedi-visna" :
3 publications dans cette catégorie
Affiliations :
Ege University Faculty of Science Department of Biology Molecular Biology Section, İzmir, Türkiye; Ege University Vaccine Development Application and Research Center, İzmir, Türkiye.
Publications dans "Virus maedi-visna" :
3 publications dans cette catégorie
Affiliations :
Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand. duncan_r_smith@hotmail.com.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Inner Mongolia Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot 010018, China.
Key Laboratory of Clinical Diagnosis and Treatment Technology for Animal Disease, Ministry of Agriculture, Hohhot 010018, China.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Anatomy and Physiology of Farm Animals, Department of Animal Science, Agricultural University of Athens (AUA), Iera Odos 75 str., 11855 Athens, Greece.
Publications dans "Virus maedi-visna" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Anatomy and Physiology of Farm Animals, Department of Animal Science, Agricultural University of Athens (AUA), Iera Odos 75 str., 11855 Athens, Greece.
Publications dans "Virus maedi-visna" :
Polymers via high internal phase emulsion (polyHIPEs) were molecularly imprinted with Irbesartan, an antihypertensive drug belonging to the class of angiotensin II receptor antagonists (sartan drugs),...
The reported primary dementia-protective benefits of angiotensin II type 1 receptor (AT...
Background The renin-angiotensin system plays a crucial role in human physiology, and its main hormone, angiotensin, activates 2 G-protein-coupled receptors, the angiotensin type-1 and type-2 receptor...
Thrombotic microangiopathy (TMA) on kidney biopsy is a pattern of endothelial injury commonly seen in malignant hypertension (mHTN), but treatment strategies are not well established....
To evaluate the kidney outcomes of angiotensin receptor-neprilysin inhibitor (ARNI), specifically sacubitril/valsartan, vs angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocke...
This single-center cohort study enrolled consecutive patients in China diagnosed with mHTN-associated TMA through kidney biopsy from January 2008 to June 2023. Follow-up was conducted until the conclu...
Treatment with sacubitril/valsartan or ACEI/ARBs during hospitalization and after discharge....
The primary outcome was a composite of kidney recovery: a 50% decrease in serum creatinine level, decrease in serum creatinine levels to the reference range, or kidney survival free from dialysis for ...
Among the 217 patients (mean [SD] age, 35.9 [8.8] years; 188 men [86.6%]) included in the study, 66 (30.4%) received sacubitril/valsartan and 151 (69.6%) received ACEI/ARBs at baseline. Sacubitril/val...
In this cohort study, sacubitril/valsartan treatment was associated with a potential kidney function benefit in patients with mHTN-associated TMA compared with ACEI/ARB treatment. The findings suggest...
The superiority of angiotensin receptor-neprilysin inhibitor (ARNI) over angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) has not been reassessed after the public...
Medications used to treat hypertension may affect fracture risk. This study investigated fracture risk for users of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers ...
Angiotensin receptor blockers (ARBs) used in the treatment of hypertension and potentially in SARS-CoV-2 infection exhibit inverse agonist effects at angiotensin AR1 receptors, suggesting the receptor...
The aim of this study was to conduct a systematic review and meta-analysis to investigate the effect of the premorbid use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker...
Embase, the Cochrane Central Register of Controlled Trials, and MEDLINE were searched for studies based on the below eligibility criteria. The protocol was registered at the PROSPERO (CRD42022309129)....
Eligibility criteria were as follows: (1) randomized controlled trials, cohort studies, cross-sectional studies, (2) patients with sepsis aged ≥16 years, and (3) received premorbid ACEI/ARB, or not....
The patient and study characteristics and outcomes were extracted. All analyses were presented with the use of random-effects models. The primary outcome was short-term mortality defined as ≤30-day, i...
Fifteen studies (N = 96,159) met the eligibility criteria. Of these, eleven studies (N = 40,360) reported unadjusted short-term mortalities. The pooled odds ratio (OR) of short-term mortality with the...
In this meta-analysis, the premorbid ACEI/ARB was associated with significantly lower short-term mortality in patients with sepsis despite the significantly higher risk of AKI....
Guidelines suggest that adults with diabetes and kidney disease receive treatment with angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). This is an update of a Co...
We compared the efficacy and safety of ACEi and ARB therapy (either as monotherapy or in combination) on cardiovascular and kidney outcomes in adults with diabetes and kidney disease....
We searched the Cochrane Kidney and Transplants Register of Studies to 17 March 2024 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register...
We included studies evaluating ACEi or ARB alone or in combination, compared to each other, placebo or no treatment in people with diabetes and kidney disease....
Two authors independently assessed the risk of bias and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their...
One hundred and nine studies (28,341 randomised participants) were eligible for inclusion. Overall, the risk of bias was high. Compared to placebo or no treatment, ACEi may make little or no differenc...
ACEi or ARB may make little or no difference to all-cause and cardiovascular death compared to placebo or no treatment in people with diabetes and kidney disease but may prevent kidney failure. ARB ma...
For persons with proteinuria, angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) are treatment mainstays for reducing kidney disease progression. Guidelines f...